DFTX Chief Medical Officer Daniel Karlin Sells $452K of Stock
Chief Medical Officer Daniel Karlin sold over 10,000 shares of Definium Therapeutics on June 25, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Daniel Karlin, Chief Medical Officer at Definium Therapeutics, Inc. ($DFTX), sold 10,035 shares at an average price of $45.03, worth about $451,876.05, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $DFTX is down 1.3% after 1 week, down 4.8% after 1 month and down 28.3% to date (from the $44.79 close on Jun 25, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- On June 25, 2026, Chief Medical Officer Daniel Karlin sold 10,035 shares of Definium Therapeutics for $451,876.
- The stock closed at $44.95 on the day of the sale, close to its 52-week high of $49.70.
- Definium has a strong buy rating from analysts, with a mean price target of $71.65.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Definium Therapeutics, Inc.
On June 25, 2026, Daniel Karlin, the Chief Medical Officer of Definium Therapeutics, Inc. (DFTX), sold 10,035 shares for about $451,876. This sale occurred as the stock trades near its 52-week high of $49.70, closing at $44.95 on that day. This transaction was part of a planned selling strategy, indicating a structured approach rather than an immediate response to market conditions.
Other Executives Also Sold Shares
Karlin wasn't alone in selling shares on June 25. Chief Financial Officer Brandi Roberts sold 3,013 shares, valued at $135,675. Chief Legal Officer Mark Sullivan sold 13,008 shares worth about $585,750, while Chief Commercial Officer Matthew Wiley sold 2,867 shares valued at over $129,000. Each of these transactions was also part of planned strategies, reflecting a broader trend among the company's leadership.
Stock Performance and Analyst Ratings
Definium Therapeutics has seen its stock trading close to its 52-week high, which indicates strong market interest. Analysts have a positive outlook on the stock, with a consensus recommendation of strong buy and a mean price target of $71.65. The stock's performance aligns with recent analyst upgrades, including a new Overweight rating from JP Morgan, which set a target of $84 on October 9, 2026.
Recent Earnings
Definium Therapeutics is expected to report its next earnings on November 5, 2026. The company has faced challenges, reflected in its negative earnings per share of -$3.43. Investors will be looking for improvements in revenue and strategies to enhance profitability in the upcoming report.
What Definium Therapeutics, Inc. Does
Definium Therapeutics develops treatments for brain health disorders, including anxiety and autism spectrum disorder. The company has several product candidates in various stages of clinical trials, which are critical for its future growth and market position.
What to Watch at Definium Therapeutics, Inc.
Investors should keep an eye on Definium's upcoming earnings report in November, which could provide insights into the company's financial health and impact from recent insider transactions. The recent insider selling does not necessarily indicate a lack of confidence in the company's future, as these moves were part of planned strategies. Overall, the company's strong analyst ratings suggest continued interest in its prospects.
Related Filing Alerts
Source: Daniel Karlin's Form 4 filing on $DFTX (Jun 25, 2026). Find the original filing: DFTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts